12 Best Multibagger Stocks to Buy Heading into 2026

Page 2 of 11

10. DBV Technologies S.A. (NASDAQ:DBVT)

Market Cap: $723.20 Million

Price Return over 1-Year: 602.49%

Upside Potential: 77.38%

Number of Hedge Fund Holders: 9

With strong 1-year returns and upside potential, DBV Technologies S.A. (NASDAQ:DBVT) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.

On December 17, 2025, H.C. Wainwright raised its price target on DBV Technologies S.A. (NASDAQ:DBVT) from $35 to $40, while reiterating a “Buy” rating, The Fly reported. The firm described the Phase 3 VITESSE trial as a clear execution milestone that materially de-risks the VIASKIN Peanut program. With the company reporting strong results in 4-7-year-old peanut-allergic children, the analyst’s confidence in a straightforward regulatory path is reinforced, supporting a Biologics License Application (BLA) submission in the first half of 2026.

The previous day, DBV Technologies S.A. (NASDAQ:DBVT) announced that its pivotal VITESSE study met its primary endpoint. After 12 months of VIASKIN Peanut patch treatment, 46.6% of children achieved clinically meaningful desensitization, compared with 14.8% on placebo. This is a statistically significant outcome that exceeded prespecified thresholds. Furthermore, the trial showed a favorable safety profile, high compliance, and low discontinuation rates. With these positive trial results, the company reinforced the patch’s potential as a non-invasive treatment option.

The positive trial results also drew the attention of the investment banking firm Citizens, which raised its price target from $21 to $45 on December 17, 2025, while maintaining an “Outperform” rating, according to The Fly. Beyond clinical efficacy, the bank expects VITESSE’s success to accelerate warrant exercises and potentially unlock $181 million in cash. According to DBV Technologies S.A. (NASDAQ:DBVT), this could be sufficient to support a potential U.S. launch in the 4-7-year-old population.

These analyst views reflect how clinical success and financial flexibility are converging for DBV as it advances toward regulatory submission.

DBV Technologies S.A. (NASDAQ:DBVT) focuses on developing non-invasive immunotherapies, led by its VIASKIN patch technology. The patch aims at desensitizing patients with food allergies and addresses significant unmet needs in pediatric care.

Page 2 of 11